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ABSTRACT 
Aims: To evaluate the effects of digoxin in patients with the newly described phenotype of 
heart failure (HF) and mid-range ejection fraction (HFmrEF), attributed to mild left 
ventricular systolic dysfunction.  
Methods and Results: We carried out a retrospective analysis of the Digitalis Investigators 
Group trial (DIG) which had 7788 patients available for analysis with a left ventricular 
ejection fraction (LVEF) ranging between 3% and 85%. We compared the effect of digoxin 
to placebo in three mutually exclusive groups of patients defined by LVEF category: <40% 
(HF with reduced LVEF, HFrEF, n=5874), 40-49% (HFmrEF, n=1195) and ≥50% (HF with 
preserved LVEF, HFpEF, n=719).  The primary outcome was the composite of 
cardiovascular death or HF hospitalization. Patients with HFmrEF resembled patients with 
HFrEF, more than those with HFpEF, with respect to age, sex and aetiology but were more 
like HFpEF patients with respect to blood pressure and the prevalence of hypertension. Event 
rates in patients with HFmrEF were similar to those in HFpEF and much lower than in 
HFrEF. Digoxin reduced the primary endpoint in patients with HFrEF, mainly due to reduced 
HF hospitalisation: the digoxin/placebo hazard ratio for HF hospitalisation was 0.71 (0.65-
0.77). The digoxin/placebo hazard ratio for heart failure hospitalisation in patients with 
HFmrEF was 0.80 (0.63-1.03) and 0.85 (0.62-1.17) in those with HFpEF. The 
digoxin/placebo hazard ratio for the composite of HF death or HF hospitalisation was 0.74 
(0.68, 0.81) in HFrEF, 0.83 (0.66, 1.05) in HFmrEF and 0.88 (0.65, 1.19) in HFpEF. 
Conclusions: In this study, event-rates in patients with HFmrEF were closer to those in 
HFpEF than HFrEF. Digoxin had most effect on HF hospitalization in patients with HFrEF, 
an intermediate effect in HFmrEF and the smallest effect in HFpEF. 
 
 
Page 4 of 26 
 
Keywords: heart failure with mid-range ejection fraction; digoxin; outcome 
 
 
 
 
 
Page 5 of 26 
 
INTRODUCTION 
In 2016, the European Society of Cardiology (ESC) guidelines on heart failure introduced the 
term heart failure with mid-range ejection fraction (HFmrEF) to describe patients with a left 
ventricular ejection fraction (LVEF) in the range 40-49%.1  These are patients who neither 
have a clearly reduced LVEF (i.e. do not have heart failure with reduced ejection fraction, 
HFrEF, the phenotype of patients enrolled in the majority of previous clinical trials) nor a 
near normal or normal (“preserved”) LVEF i.e. ≥50% (here after referred to as HFpEF).  
Patients with a LVEF 40-49% were either the minority of those enrolled in prior trials, or 
were excluded from previous trials, and represent a “grey area” with respect to 
pathophysiological understanding and treatment choices.2-4   
 
The ESC guidelines suggested that patients with HFmrEF may represent an intermediate 
phenotype, likely characterised by the presence of mild left ventricular systolic dysfunction..1 
One way to test the hypothesis is to examine the effect of treatments that are known to be 
beneficial in HFrEF in patients with HFmrEF. Perhaps the prototypical agent of this type is 
digoxin. As an inotrope, digoxin might be expected to be of benefit in systolic dysfunction 
but not in diastolic dysfunction. The Digitalis Investigators Group trial (DIG) which enrolled 
patients with a LVEF ranging between 3% and 85% offered the opportunity to compare the 
effect of digoxin in HFrEF, HFmrEF and HFpEF.5, 6  We have carried out a retrospective 
analysis of the effect of digoxin in patients with HFmrEF in DIG.
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METHODS 
DIG inclusion and exclusion criteria  
The rationale, design and results of DIG have been published.5, 6 Patients were randomised at 
302 clinical centres in the United States and Canada. The study was approved by the ethics 
committee at each participating centre and all patients gave written informed consent. 
Patients were eligible for the main trial if they had heart failure and a LVEF fraction of 45% 
or less and were in normal sinus rhythm (6800 patients).5 Patients with heart failure and a 
LVEF of more than 45% were enrolled in an ancillary trial conducted in parallel to the main 
trial (988 patients).6 The diagnosis of heart failure was based on current or previous 
symptoms (limitation of activity, fatigue, and dyspnoea or orthopnea), signs (oedema, 
elevated jugular venous pressure, rales, or a third heart sound/gallop rhythm), or radiologic 
evidence of pulmonary congestion. Exclusion criteria included a serum potassium 
concentration less than 3.2 mmol/l or above 5.5 mmol/l and significant renal insufficiency 
(creatinine greater than 3.0 mg/dl) or severe liver disease. Investigators were strongly 
encouraged to give study patients an angiotensin-converting–enzyme inhibitor.5, 6 
 
Study drug randomisation and dosing and trial outcomes 
Patients were randomly assigned to receive digoxin or placebo and follow-up visits took 
place at 4 weeks and 16 weeks after randomisation and every 4 months thereafter.5, 6  
The primary outcome in DIG was death from any cause. The trial secondary outcomes 
included death from cardiovascular causes, death from worsening heart failure, and 
hospitalization for worsening heart failure.5, 6 For the purposes of the present study, we used 
the composite of cardiovascular death or heart failure hospitalization as the primary outcome, 
reflecting the most commonly used endpoint in contemporary heart failure trials. 
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LVEF categories (definition of HFrEF, HFmrEF and HFpEF) 
For the purposes of comparing the clinical characteristics of and outcomes in HFrEF, 
HFmrEF and HFpEF, patients were divided into three mutually exclusive LVEF categories: 
less than 40% (HFrEF), 40-49% (HFmrEF), and greater than or equal to 50% (HFpEF).1 
 
Statistical analysis  
We had full access to anonymised individual-patient data via the Virtual international 
Cardiovascular and Cognitive Trials Archive (VICCTA).7, 8  Descriptive statistics were used 
to compare patients across the three LVEF categories. Data are presented as means (standard 
deviation [SD]) or medians (inter-quartile range [IQR]) for continuous variables and 
frequency (percent) for categorical variables. We examined the effect of randomised 
treatment on the following major clinical outcomes: the composite of cardiovascular (CV) 
death or heart failure (HF) hospitalisation (primary endpoint for the present study); the 
composite of HF death or HF hospitalisation (a pre-specified composite outcome in the DIG 
and considered to be the outcome most sensitive to the effect of digoxin); the components of 
these composites; and all-cause death (the pre-specified primary endpoint in DIG).  
Comparison of clinical outcomes among treatment groups was performed using Kaplan-
Meier estimates, with log-rank test, and a supportive Cox proportional-hazards regression 
model to calculate hazard ratios and 95% confidence intervals. The reported hazard ratios 
were adjusted for age and sex. The interaction between LVEF category and the effect of 
treatment was also examined for each clinical outcome. The analyses were undertaken using 
SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA).    
The interaction between LVEF as a continuous variable and the effect of treatment on the 
composite outcome was also examined and graphically displayed using fractional polynomial 
function.9  The rates of the composite outcome across LVEF was examined using the 
Page 8 of 26 
 
restricted cubic spline method. The fractional polynomial and restricted cubic spline analyses 
were undertaken using the mfpi and incspline commands respectively in STATA version 14 
(College Station, TX, USA).  
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RESULTS 
There were 7788 patients with a LVEF available for analysis in the public use version of the 
DIG database.  The median LVEF was 30% (IQR 23 to 39%). Of the 7788 patients analysed, 
5874 (75%) had HFrEF, 1195 (15%) HFmrEF and 719 had HFpEF (9%). 
 
Baseline characteristics 
The baseline characteristics of the patients in each LVEF category are shown in Table 1.  The 
characteristics of patients with HFmrEF were intermediate between the other two groups.  In 
terms of age (HFmrEF 64.5 versus HFrEF 63.4 versus HFpEF 67.3 years), sex (female 28.9 
versus 21.1 versus 47.4%, respectively), and history of myocardial infarction (63.1 versus 
65.3 versus 44.7%, respectively), HFmrEF patients were more similar to patients with HFrEF 
than those with HFpEF.  Conversely, with respect to history of hypertension (HFmrEF 53.6 
versus HFrEF 44.0 versus HFpEF 62.5%, respectively), blood pressure (systolic pressure 
133.4 versus 124.6 versus 138.9 mmHg, respectively), heart rate (76.1 versus 79.1 versus 
76.2 bpm, respectively) and renal function (creatinine 110.5 versus 113.9 versus 111.2 µmol/l, 
respectively), HFmrEF patients resembled those with HFpEF more than individuals with 
HFrEF. 
 
Symptoms and signs of heart failure 
With two exceptions, the prevalence of all symptoms and signs was lowest in patients with 
HFmrEF, compared to the other two LVEF categories (Table 2). The exceptions were 
dyspnoea at rest or on exertion which had the same prevalence in HFmrEF and HFrEF 
(95.2%), compared with HFpEF (96.9%) and the frequency of a third heart sound gallop 
rhythm which was considerably less common in both patients with HFmrEF (37.9%) and 
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HFpEF (33.0%) than in those with HFrEF (51.9%). Cardiothoracic ratio was also lower in 
patients with HFmrEF (0.51) and HFpEF (0.52) than in individuals with HFrEF (0.53). 
 
Clinical outcomes 
Comparison of the primary composite outcome in the placebo group across LVEF categories 
showed a significantly higher rate in the HFrEF patients compared with the other two groups 
(Table 3, Figures 1 and 2).  The rate of this endpoint was similar in HFmrEF and HFpEF 
groups (Table 3, Figure 1).  The same was true for each component of the composite i.e. 
cardiovascular death and heart failure hospitalisation separately and the pre-specified DIG 
composite of heart failure death or heart failure hospitalisation (and its components).  
A similar pattern was observed for all-cause death (Table 3).  Overall, 86.0% of deaths in 
patients with HFrEF were due to a cardiovascular cause; this proportion was 74.4% in 
patients with HFmrEF and 78.4% in patients with HFpEF. 
The restricted cubic spline analysis suggested a LVEF inflection point of around 35%, below 
which the rate of the primary composite outcome increased linearly (Figure 2). 
 
Effect of digoxin 
Digoxin reduced the risk of the primary composite outcome in patients with HFrEF, an effect 
mainly due to significant reduction in heart failure hospitalisation: the digoxin/placebo hazard 
ratio for HF hospitalisation in patients with HFrEF was 0.71 (0.65-0.77) (Table 3).  The 
digoxin/placebo hazard ratio for heart failure hospitalisation in patients with HFmrEF was 
0.80 (0.63-1.03) and 0.85 (0.62-1.17) in those with HFpEF (Table 3).  The digoxin/placebo 
hazard ratio for the composite of HF death or HF hospitalisation was 0.74 (0.68, 0.81) in 
patients with HFrEF, 0.83 (0.66, 1.05) in those with HFmrEF and 0.88 (0.65, 1.19) in 
participants with HFpEF. 
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The fractional polynomial analysis showed a clear benefit of digoxin on the primary 
composite endpoint up to a LVEF of around 35%, with a smaller, if any, effect above that 
value although the interaction p-value examining effect of digoxin according to LVEF was 
0.604 (Figure 3).
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DISCUSSION 
Prior studies of ambulatory cohorts have shown that approximately 10-20% of patients with 
heart failure have a LVEF in the range 40-49% i.e. have the newly designated category of 
HFmrEF.  We found that 15% of patients in DIG fell within this category, consistent with the 
17% of 7598 patients in the Candesartan in Heart Failure: Assessment of Mortality and 
morbidity (CHARM), 15% of 9134 patients the ESC Heart Failure Long-Term Registry and 
13% of a Spanish cohort of 3446 patients.10-13 However, the largest study (n=41,446) of 
ambulatory patients from Sweden found that 21.5% had HFmrEF.14  It is not clear why the 
Swedish cohort had a higher prevalence than the other studies, especially the ESC registry, 
although our patients all were in sinus rhythm whereas the Swedish Registry included many 
patients with atrial fibrillation (65%, 60%, and 53% in HFpEF, HFmrEF and HFrEF, 
respectively). 
 
We found that patients with HFmrEF resembled patients with HFrEF, more than those with 
HFpEF, with respect to age, sex and aetiology (particularly ischaemic aetiology).  On the 
other hand, blood pressure and the prevalence of hypertension were higher in patients with 
HFmrEF than in patients with HFrEF, although not as high as in HFpEF.  This pattern is 
consistent with the prior studies alluded to earlier. 
 
Despite the similarities to HFrEF mentioned above, the rates of non-fatal and fatal heart 
failure events were considerably lower in patients with HFmrEF and much more like those in 
HFpEF (at around half the rate of these events in patients with HFrEF).  Again, this finding 
was very similar to what was seen in CHARM, the ESC Long-Term Registry in the Spanish 
cohort and in a recent analysis of beta-blocker trials (see below).10-13, 15 
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The unique aspect of the present study was the evaluation of the effect of digoxin according 
to LVEF category.  Overall, in DIG, the predominant effect of digoxin was on hospital 
admission for heart failure and the composite of death from heart failure or hospitalization for 
heart failure.5  The size of the effect of digoxin treatment on this heart failure hospitalisation 
(and composites of this with either heart failure death or cardiovascular death) was larger in 
patients with HFrEF than in those with either HFmrEF or HFpEF.  The effect of digoxin, if 
any, was similar (and small) in patients with HFmrEF and HFpEF.   
It is of interest to compare these findings with similar analyses from CHARM and the 
Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial 
(TOPCAT). 12, 13 Notably, none of the CHARM-Preserved, DIG or TOPCAT trials were 
positive for their primary endpoint but, interestingly, all three showed an overall significant 
reduction in HF hospitalization (arguably the endpoint most “sensitive” to the effect of a drug 
in heart failure).  If we look at the effect of treatment on this endpoint in patients with 
HFmrEF in each of these 3 trials we see: CHARM (n= 1322 patients with HFmrEF) 
candesartan/placebo hazard ratio [HR] 0.72 (0.55-0.95); TOPCAT (n=520) 
spironolactone/placebo HR 0.76 (0.46, 1.27); and DIG (n=1195) digoxin/placebo HR 0.80 
(0.63-1.03), all of which overlap. Only CHARM showed a nominally statistically significant 
effect of study drug. Where the three trials differ is in relation to cardiovascular (CV) death: 
here the HRs were CHARM 0.81 (0.60-1.11), TOPCAT 0.69 (0.43, 1.12) and DIG 1.24 
(0.94-1.64) and hence the composite of CV death or HF hospitalization: CHARM 0.76 (0.61-
0.96), TOPCAT 0.72 (0.50, 1.05) [the TOPCAT primary also included a few cases of 
resuscitated cardiac arrest] and DIG 0.96 (0.79-1.17). In another recent report, 575 patients 
with HFmrEF were included in a meta-analysis of beta-blocker trials. Unfortunately, HF 
hospitalization was not reported as an endpoint but there was the suggestion that fatal 
outcomes might be reduced by beta-blockers in patients in this subgroup in sinus rhythm but 
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the numbers were small and the estimate of treatment effect uncertain/unreliable. This benefit 
was not as apparent for the non-fatal outcome examined which was CV hospitalization (or the 
composite of CV death or CV hospitalization). 
The discrepancy between the studies may reflect the play of chance, given that all analyses 
were retrospective and had only moderate power or it may represent true differences in 
responsiveness to distinct pharmacological interventions among the three heart failure 
phenotypes identified.  Beta-blockers and angiotensin converting enzyme (ACE) inhibitors 
(and probably ARBs) are beneficial in patients with coronary artery disease (and 
hypertension and diabetes), even in the absence of a reduced LVEF.  No such suggestion has 
been made for digoxin in patients in sinus rhythm.  Hence, beta-blockers and candesartan 
may truly have had a beneficial effect on cardiovascular mortality in patients with HFmrEF 
whereas such a benefit might not have been anticipated with digoxin. Interpretation   of the 
effect of spironolactone is more difficult. This drug does not seem to reduce mortality in 
patients with a normal or near-normal LVEF and whether there is a mortality benefit in 
patients with HFmrEF is uncertain because of the small size of this subgroup in TOPCAT 
and the resultant wide confidence intervals around the estimate of treatment-effect in these 
patients.   
It is important to expression a word of caution about all three of these studies. The 
retrospective nature and low power of each has been alluded to above. The beta-blocker 
analyses did not report tests of whether there was an interaction between treatment effect and 
LVEF (using LVEF as either a categorical or as a continuous variable) and in both CHARM 
and DIG, where such tests were done, they were not significant for the primary composite 
outcome, cardiovascular death or HF hospitalization. Although such tests have low power, 
they suggest that we cannot definitively conclude that the effect of the treatments reviewed 
differ according to LVEF, even if the overall impression is that they do. This is a significant 
Page 15 of 26 
 
limitation of all 3 analyses discussed. The TOPCAT investigators could not do a similar 
analysis because the trial did not include patients with a LVEF <45%. 
 
That all patients in DIG were in sinus rhythm is both a weakness and a strength of this 
analysis – clearly many patients with HF do have atrial fibrillation but inclusion of those only 
in sinus rhythm removed the confounding influence of this arrhythmia when interpreting 
outcomes and effect of therapy. DIG is also an old dataset, collected at a time when neither 
beta-blockers or mineralocorticoid receptor antagonists were routinely used to treat patients 
with HF. Again, this is both a weakness and strength. While the effects of digoxin might be 
less in patients treated with contemporary therapy, lack of two of these therapies makes it 
easier to identify the effect of digoxin. Lack of these treatments also makes it less likely that 
the HFmrEF patients in DIG included many patients with “recovered LVEF” i.e. the HFmrEF 
patients in DIG were likely a more homogenous group than in more current cohorts.2, 16 
 
In summary, while patients with HFmrEF exhibited some similarities to those with HFrEF in 
terms of baseline characteristics, their rates of fatal and non-fatal heart failure events were 
substantially lower than in individuals with HFrEF. This and a smaller effect of digoxin on 
HF hospitalization in patients with HFmrEF do not support the view that left ventricular 
systolic dysfunction is as important in this type of heart failure as in HFrEF. 
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FIGURE LEGENDS 
Figure 1. Kaplan-Meier cumulative risk of composite outcome of CV death or HF 
hospitalisation according to LVEF stratum. 
 
 
Figure 2. Incidence rate of composite outcome of CV death or HF hospitalisation according 
to LVEF (spline analysis) 
Point estimates (the black solid line) and 95% confidence intervals (area between the dotted lines) for the rates 
of the composite outcome of cardiovascular death or heart failure hospitalisation according to LVEF. Rates are 
shown as per 100 patient-years. 
 
 
 
Figure 3. Effect of digoxin on the composite outcome of CV death or HF hospitalisation 
according to LVEF (fractional polynomial analysis). 
Digoxin to placebo hazard ratio (the black solid line) and 95% confidence interval (area between the dotted lines) 
for the composite outcome of cardiovascular death or heart failure hospitalisation according to LVEF. A hazard 
ratio of 1.0 is indicated by the solid horizontal line. A hazard ratio of <1.0 favours digoxin. 
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TABLES 
Table 1. Baseline characteristics according to the ejection fraction stratum. 
 
HFrEF 
(n=5874) 
HFmrEF  
(n=1195) 
HFpEF  
(n=719) 
p-value 
Demographics, n (%)    
 
Age, year 63.4 ±10.9 64.5 ±10.6 67.3 ±10.4 <0.001 
Caucasians 5010 (85.3) 1034 (86.5) 616 (85.7) 0.538 
Female sex 1240 (21.1) 345 (28.9) 341 (47.4) 
<0.001 
NYHA class  <0.001 
I 757 (12.9) 197 (16.5) 149 (20.7)  
II 3095 (52.7) 745 (62.3) 397 (55.2)  
III 1886 (32.1) 240 (20.1) 161 (22.4)  
IV 131 (2.2) 12 (1.0) 11 (1.5)  
Duration of heart failure, year    2.5 ±3.1 2.4 ±2.9 2.2 ±2.8 0.041 
LV Ejection Fraction, % 26.4 ±7.5 43.3 ±2.8 58.5 ±7.6 <0.001 
Cardiothoracic ratio 0.53 ±0.1  0.51 ±0.1  0.52 ±0.1  <0.001 
No. of signs or symptoms of CHF†    <0.001 
0 67 (1.1) 9 (0.8) 4 (0.6)  
1 125 (2.1) 33 (2.8) 7 (1.0)  
2 379 (6.5) 131 (11.0) 39 (5.4)  
3 499 (8.5) 145 (12.1) 60 (8.3)  
   ≥4 4802 (81.8) 877 (73.3) 609 (84.7)  
 
Baseline vital signs    
 
BP, mmHg     
Systolic 124.6 ±19.6 133.4 ±19.9 138.9 ±21.9 <0.001 
Diastolic 74.6 ±11.3 77.1 ±10.7 76.5 ±11.7 <0.001 
Heart rate, beats/min 79.1 ±12.7 76.1 ±12.1 76.2 ±11.8 <0.001 
BMI, kg/m2 27.0 ±5.2  27.7 ±5.2 29.0 ±6.7 <0.001 
Serum creatinine, µmol/L 113.9 ±32.4  110.5 ±32.9 111.2 ±35.8  0.001 
 
Medical history, n (%) 
   
 
Myocardial Infarction 3833 (65.3) 754 (63.1) 321 (44.7) <0.001 
Angina 1553 (26.4) 350 (29.3) 212 (29.5) 0.043 
Hypertension 2585 (44.0) 640 (53.6) 449 (62.5) <0.001 
Diabetes 1647 (28.0) 362 (30.3) 209 (29.1) 0.264 
Previous digoxin use 2655 (45.2) 446 (37.3) 264 (36.7) <0.001 
 
Medication, n (%) 
 
 
Potassium-sparing diuretic 452 (7.7) 91 (7.6) 53 (7.4) 0.907 
Other diuretics 4669 (79.5) 841 (70.4) 566 (78.7) <0.001 
ACE inhibitor  5576 (94.9) 1081 (90.5) 617 (85.8) 0.097 
Nitrate  2508 (42.7) 497 (41.6) 282 (39.2) <0.001 
Hydralazine 114 (1.9) 31 (2.6) 13 (1.8) <0.001 
     
Randomised to digoxin 2932 (49.9) 607 (50.8) 350 (48.7) 0.668 
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All continous values are given in mean ± standard deviation unless stated otherwise. n(%): number of 
observations (percentage of observations within the group). HFrEF: heart failure with redcued ejection fraction. 
HFmrEF: heart failure with mid-range ejection fraction. HFpEF: heart failure with preserved ejection fraction. 
LV: left ventricle. CHF: chronic heart failure.  NYHA: New York Heart Association. BMI: body mass index. 
ACE: angiotensin converting enzyme.  
 
† The clinical signs or symptoms studied included rales, elevated jugular venous pressure, peripheral oedema, 
dyspnoea at rest or on exertion, orthopnoea, limitation of activity, S3 gallop and radiological evidence of 
pulmonary congestion. 
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Table 2. Clinical signs or symptoms as baseline according to the ejection fraction stratum. 
 
HFrEF 
(n=5874) 
HFmrEF 
(n=1195) 
HFpEF  
(n=719) 
p-value 
Presence of clinical signs or symptoms     
Limitation of activity 5464 (93.0) 1082 (90.5) 672 (93.5) 0.008 
Dyspnoea at rest or on exertion 5593 (95.2) 1138 (95.2) 697 (96.9) 0.128 
Orthopnoea 4186 (71.3) 759 (63.5) 521 (72.5) <0.001 
Peripheral oedema 3054 (52.0) 610 (51.1) 449 (62.5) <0.001 
Elevated jugular venous pressure 3142 (53.5) 527 (44.1) 356 (49.5) <0.001 
Rales 4233 (72.1) 788 (65.9) 544 (75.7) <0.001 
Radiological pulmonary congestion 4026 (68.5) 706 (59.1) 461 (64.1) <0.001 
S3 gallop 3049 (51.9) 453 (37.9) 237 (33.0) <0.001 
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Table 3. Clinical outcomes accoridng to ejection fraction stratum and randomised treatment assignment. 
 
 HFrEF (<40%) HFmrEF (40-49%) HFpEF (≥50%) p-value for 
interaction Outcome, n (rate) Placebo 
(n= 2942) 
Digoxin 
(n= 2932) 
HR (95% CI) Placebo 
(n= 588) 
Digoxin 
(n= 607) 
HR (95% CI) Placebo 
(n= 369) 
Digoxin 
(n= 350) 
HR (95% CI) 
CV death or HF 
hospitalisation 
1498 (22.2) 1344 (18.3) 0.83 (0.77-0.89) 194 (11.9) 198 (11.5) 0.96 (0.79-1.17) 119 (12.1) 107 (10.8) 0.92 (0.71-1.20) 0.327 
- CV death 
 
929 (11.0) 926 (10.9) 0.99 (0.91-1.09) 90 (4.8) 113 (6.0) 1.24 (0.94-1.64) 71 (6.3) 67 (6.2) 1.03 (0.74-1.44) 0.326 
- HF hospitalisation 1067 (15.8) 812 (11.0) 0.71 (0.65-0.77) 139 (8.5) 118 (6.9) 0.80 (0.63-1.03) 82 (8.3) 69 (6.9) 0.85 (0.62-1.17) 0.395 
 
HF death or HF 
hospitalisation 
 
 
1168 (17.3) 
 
932 (12.7) 
 
0.74 (0.68-0.81) 
 
152 (9.3) 
 
134 (7.8) 
 
0.83 (0.66-1.05) 
 
90 (9.1) 
 
77 (7.7) 
 
0.88 (0.65-1.19) 
 
0.448 
- HF death 
 
422 (5.0) 371 (4.4) 0.87 (0.76-1.01) 31 (1.7) 29 (1.5) 0.93 (0.56-1.55) 30 (2.7) 24 (2.2) 0.89 (0.52-1.52) 0.959 
All-cause death 
 
1091 (12.9) 1066 (12.6) 0.97 (0.89-1.06) 130 (7.0) 143 (7.6) 1.08 (0.85-1.37) 89 (7.9) 87 (8.0) 1.06 (0.79-1.42) 0.693 
 Rate per 100 patient years. CV=cardiovascular. HF=heart failure. P-value for interaction between treatment groups with ejection fraction categories.  
All reported hazard ratios were adjusted for age and sex. 
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